Despite the need for novel, effective therapeutics for the COVID-19 pandemic, no curative
regimen is yet available, therefore patients are forced to rely on supportive and nonspecific …

Nirmatrelvir/ritonavir (Paxlovid™) is an effective and safe antiviral drug that inhibits the main
protease (Mpro), 3CL protease, of SARS-CoV-2. A reduction in COVID-19-related …

Background Safe and effective oral treatments are needed to improve clinical outcomes for
nonhospitalized patients with Covid-19. Molnupiravir is an orally administered, small …

On 4 th November 2021, the first oral antiviral drug for COVID-19, molnupiravir (Lagevrio®),
received full regulatory approval from the Medicines and Healthcare Products Regulatory …

The use of antiviral COVID-19 medications can successfully inhibit SARS-CoV-2 replication
and prevent disease progression to a more severe form. However, the timing of antiviral …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background The coronavirus disease (COVID-19) epidemic has not been completely
controlled. Although great achievements have been made in COVID-19 research and many …

Molnupiravir and nirmatrelvir were the first available oral antivirals (OAs) active against
SARS-CoV-2. Trials evaluating the efficacy of OAs involved patients unvaccinated and …

The landscape of development of treatment modalities and preventive measures for COVID-
19 has progressed expeditiously since the beginning of the pandemic. We included all the …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …